Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213165 | 1.00 | GRIN2D (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL13351566 | 0.85 | APP (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6449354 | 0.81 | ADRA2A (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6449359 | 0.81 | ADRA2A (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL215311 | 0.81 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL211596 | 0.81 | KMT2A (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL211595 | 0.81 | KMT2A (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12017600 | 0.81 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12957594 | 0.81 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10079375 | 0.80 | ADRA2A (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077941-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | US | claimed |
| US-8088868-B2 | oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis | BRIDGESTONE CORPORATION (JP) | 2012-01-03 | — | — | US | claimed |
| US-20080146745-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2008-06-19 | — | — | US | claimed |
| CN-114401935-B | Ion channel antagonists/blockers and uses thereof | 上海市东方医院（同济大学附属东方医院） | 2024-04-05 | — | — | CN | disclosed |
| CN-114401935-A | Ion channel antagonists/blockers and uses thereof | 上海市东方医院（同济大学附属东方医院） | 2022-04-26 | — | — | CN | disclosed |
| WO-2021114313-A1 | ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF | SHANGHAI EAST HOSPITAL (CN) | 2021-06-17 | — | — | WO | disclosed |
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8541509-B2 | Polymers functionalized with protected oxime compounds | BRIDGESTONE CORPORATION (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20120077941-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8088868-B2 | oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis | BRIDGESTONE CORPORATION (JP) | 2012-01-03 | — | — | US | disclosed |
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20080146745-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2008-06-19 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IL2, IRF3 | GRIN2D 3376/4885GRIN3B 1824/4885GRIN1 3790/4885 |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | IFNG, IRF3, IL2 | GRIN2D 4228/4885GRIN3B 2600/4885GRIN1 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.